Journal of Cardiac Failure
Volume 12, Issue 1 , Pages 39-46 , February 2006

Warfarin Versus Aspirin in Patients With Reduced Cardiac Ejection Fraction (WARCEF): Rationale, Objectives, and Design

  • Patrick Pullicino, MD

      Affiliations

    • Department of Neurology and Neurosciences, New Jersey Medical School, UMDNJ, Newark, New Jersey
    • Corresponding Author InformationReprint requests: Patrick Pullicino, MD, Room 105, KIMHS, Research and Development Centre, University of Kent, Canterbury CT2 7PD, United Kingdom.
    • ,
  • John L.P. Thompson, PhD

      Affiliations

    • Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York
    • ,
  • Bruce Barton, PhD

      Affiliations

    • Maryland Medical Research Institute, Baltimore, Maryland
    • ,
  • Bruce Levin, PhD

      Affiliations

    • Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York
    • ,
  • Susan Graham, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, State University of New York at Buffalo
    • ,
  • Ronald S. Freudenberger, MD

      Affiliations

    • Heart Failure and Transplant Cardiology Program, Department of Medicine, Robert Wood Johnson Medical School, New Brunswick, New Jersey
    • ,
  • on behalf of the WARCEF Investigators

Received 19 June 2003 ,Revised 20 July 2005 ,Accepted 22 July 2005.

References 

  1. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J. 1997;133:703–712
  2. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KKL, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397–1402
  3. Redfield MM. Heart failure—an epidemic of uncertain proportions. N Engl J Med. 2002;347:1442–1444
  4. Rich MW. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Ger Soc. 1997;45:968–974
  5. Kannel WB, Wolf PA, Verter J. Manifestations of coronary disease predisposing to stroke. The Framingham study. JAMA. 1983;250:2942–2946
  6. Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol. 1997;29:1074–1080
  7. Loh E, Sutton MSJ, Wun CCC, Rouleau JL, Flaker GC, Gottlieb SS, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med. 1997;336:251–257
  8. Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med. 1999;340:609–616
  9. Sacco RL, Shi T, Zamanillo MC, Kargman DE. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan stroke study. Neurology. 1994;44:626–634
  10. Petty GW, Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Survival and recurrence after first cerebral infarction—a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology. 1998;50:208–216
  11. Harvey WP, Finch CA. Dicumarol prophylaxis of thromboembolic disease in congestive heart failure. N Engl J Med. 1950;242:208–211
  12. Griffith GC, Stragnell R, Levinson DC, Moore FJ, Waare AG. A study of the beneficial effects of anticoagulant therapy in congestive heart failure. Ann Int Med. 1952;37:867–887
  13. Anderson GM, Hull E. The effect of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure. Am Heart J. 1950;9:697–702
  14. Cleland JGF. Anticoagulant and antiplatelet therapy in heart failure. Curr Opin Neurol. 1997;12:276–287
  15. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med. 1990;323:147–152
  16. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group . Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet. 1994;343:499–503
  17. Sixties Plus Reinfarction Study Research Group . A double-blind trial to assess long-term oral anticoagulation therapy in elderly patients after myocardial infarction. Lancet. 1980;ii:989–994
  18. Massie BM, Krol WF, Ammon SE, Armstrong PW, Cleland JG, Collins JF, et al. The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail. 2004;10:101–112
  19. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81–106
  20. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Trial. J Am Coll Cardiol. 1998;31:419–425
  21. Leor J, Reicher-Reiss H, Goldbourt U, Boyko V, Gottlieb S, Battler A, et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 1999;33:1920–1925
  22. Katz SD, Marantz PR, Biasucci L, Jondeau G, Lee K, Brennan C, et al. Low incidence of stroke in ambulatory patients with heart failure: a prospective study. Am Heart J. 1993;126:141–146
  23. Falk RH. A plea for a trial of anticoagulation in dilated cardiomyopathy. Am J Cardiol. 1990;65:914–915
  24. Fuster V, Halperin JL. Left ventricular thrombi and cerebral embolism. N Engl J Med. 1989;320:392–394
  25. Ezekowitz M. Antithrombotics for left-ventricular impairment?. Lancet. 1998;351:1904
  26. Atrial fibrillation investigators . Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Int Med. 1994;154:1449–1457
  27. Hart RG, Halperin JL. Atrial fibrillation and stroke: revisiting the dilemmas. Stroke. 1994;25:1337–1341
  28. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335:540–546
  29. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;31:749–753
  30. Cairns JA, Lewis HD, Meade TW, Sutton GC, Theroux P. Antithrombotic agents in coronary artery disease. Chest. 1995;108:380S–440S
  31. The European Atrial Fibrillation Trial Study Group . Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 1995;333:5–10
  32. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European stroke prevention study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1–13
  33. The SALT Collaborative Group . Swedish aspirin low-dose trial (SALT) of 75mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet. 1991;338:1345–1349
  34. UK-TIA study group . The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54:1044–1054
  35. Taylor DW, Barnett HJM, Haynes RB, Ferguson GG, Sackett DL, Thorpe KE, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. Lancet. 1999;353:2179–2184
  36. CAPRIE Steering Committee . A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–1339
  37. Madsen BK, Videbaek R, Stockholm H, Mortensen LS, Hansen JF. Prognostic value of echocardiography in 190 patients with chronic congestive heart failure. A comparison with New York Heart Association functional class and radionuclide ventriculography. Cardiology. 1996;87:250–256
  38. The WARSS APASS, PICSS, HAS and GENESIS Studies . The feasibility of a collaborative double-blind study using an anticoagulant. Cerebrovasc Dis. 1997;7:100–112
  39. The Medical Research Council's General Practice Research Framework . Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998;351:233–241
  40. Siegmund DO. Sequential analysis. New York: Springer-Verlag; 1985;
  41. Whitehead J. The design and analysis of sequential clinical trials. ed 2. New York: Ellis Horwood; 1992;
  42. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN. Incidence of thromboembolic events in congestive heart failure. Circulation. 1993;87(Suppl. 6):VI94–VI101
  43. Cioffi G, Pozzoli M, Forni G, Franchini M, Opasich C, Cobelli F, et al. Systemic thromboembolism in chronic heart failure. Eur Heart J. 1996;17:1381–1389
  44. The CONSENSUS Trial Study Group . Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987;316:1429–1435

 Funded by National Institutes of Health—National Institute of Neurological Disorders and Stroke, cooperative agreements U01 NS43975 and U01 NS39143Dr. Pullicino's current affiliation is Kent Institute of Medicine and Health Sciences, University of Kent, Canterbury, United Kingdom.

PII: S1071-9164(05)00715-3

doi: 10.1016/j.cardfail.2005.07.007

Journal of Cardiac Failure
Volume 12, Issue 1 , Pages 39-46 , February 2006

Article Tools

* Image Usage & Resolution